Skip to main content
All lobbying filings

AEGIS LLC

AEGIS LLC filed a Q3 report for TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS on October 17, 2026, reporting $50,000 in lobbying income.

Lobbying for TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS · Biopharmaceutical company.

All filings by AEGIS LLC · Everything TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 17, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
New Jersey

Official filing document

 Lobbyists on this filing 1
  • ANNE ELIZABETH ESPOSITO
    Previously held: Health Policy Coordinator, Energy and Commerce Committee; Health Policy Advisor, Health Subcommittee (Chairman Bilirakis)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Pharmacy

ADHD treatment. Implementation of the Infrastructure Investment and Jobs Act (or bipartisan infrastructure law). Traffic safety (distracted and impaired driving). Issues related to FDA approval. Patient access to non-opioid pain medicines. NO PAIN Act implementation. H.R.1227 / S.475: Alternatives to PAIN Act. Most-Favored Nation (MFN) International reference pricing. Make America Healthy Again (MAHA) Commission. Proposed regulations. Global Benchmark for Efficient Drug Pricing (GLOBE) Model.

 Bills named in this filing 2

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem